NCT Number: NCT00195572
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer. Secondary endpoints include response rates, duration of responses, time to progression (TTP) safety and quality of life (QOL).
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–77 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Adachi-ku, Tokyo, Japan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Gastric cancer diagnosed histologically or cytologically
- Normal organ function of bone marrow, heart, liver and kidney
- Age of 20-77
Other inclusion applies
Exclusion criteria
- Serious infection, heart disease, complication or organ disorder
- Ongoing administration of flucytosine
- Pregnant or breastfeeding women
Other exclusion applies
Treatment and study plan
TS-1
DrugPrimary outcomes
-
Survival time
Secondary outcomes
-
Response rate, duration of response, time to progression, safety, quality of life
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Post-Approved Phase III Study of 1-LV/5FU Therapy
Important dates
- Study start
- 2002
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Sep 19, 2005
- Registry last updated
- Aug 13, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
NCT00183898
Digestive System Diseases, Digestive System Neoplasms
Los Angeles, California, United States
View Trial DetailsNutrition Intervention Trials in Linxian Follow-up Study
NCT00342654
Digestive System Diseases, Digestive System Neoplasms
Beijing, China
View Trial DetailsA Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
NCT05396300
Colonic Diseases, Colorectal Cancer
Hangzhou, Zhejiang, China
View Trial DetailsSafety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
NCT05538195
Colon Cancer, Colonic Diseases
Henan, China
View Trial Details